The future of cancer vaccines for non-small-cell lung cancer: Ongoing trials

被引：16

作者：

Choudhury, Aniruddha ^{[1
]}

Palma, Marzia ^{[1
]}

Mellstedt, Hakan ^{[1
]}

机构：

[1] Canc Centrum Karolinska, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden

来源：

CLINICAL LUNG CANCER | 2008年 / 9卷

基金：

美国国家卫生研究院;

关键词：

BLP25; cell-derived vaccines; gene-modified vaccines; GM-CSF vaccine;

D O I：

10.3816/CLC.2008.s.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer represents one of the malignancies in which the 3 elements of conventional therapy (ie, surgery, radiotherapy, and chemotherapy) have limited effectiveness in curbing progressive disease. In this context, there is burgeoning interest in the use of vaccine therapy as a nontoxic adjunct to increase the treatment success rates over those obtained with traditional regimens alone. Several clinical trials using a variety of vaccination strategies have been reported or are ongoing. In this review, we have provided an overview of these trials, with a special focus on the clinical efficacy of the vaccines. The future prospects and challenges of vaccine therapy in lung cancer have also been discussed.

引用

页码：S37 / S44

页数：8

共 25 条

[1] Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients [J].

Atanackovic, D ;

Altorki, NK ;

Stockert, E ;

Williamson, B ;

Jungbluth, AA ;

Ritter, E ;

Santiago, D ;

Ferrara, CA ;

Matsuo, M ;

Selvakumar, A ;

Dupont, B ;

Chen, YT ;

Hoffman, EW ;

Ritter, G ;

Old, LJ ;

Gnjatic, S .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3289-3296

[2] Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].

Butts, C ;

Murray, N ;

Maksymiuk, A ;

Goss, G ;

Marshall, E ;

Soulières, D ;

Cormier, Y ;

Ellis, P ;

Price, A ;

Sawhney, R ;

Davis, M ;

Mansi, J ;

Smith, C ;

Vergidis, D ;

Ellis, P ;

MacNeil, M ;

Palmer, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681

[3] Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study [J].

Chan, B ;

Lee, W ;

Hu, CXL ;

Ng, P ;

Li, KW ;

Lo, G ;

Ho, G ;

Yeung, DW ;

Woo, D .

CYTOTHERAPY, 2003, 5 (01) :46-54

[4] Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial [J].

Dancey, J ;

Shepherd, FA ;

Gralla, RJ ;

Kim, YS .

LUNG CANCER, 2004, 43 (02) :183-194

[5] Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review [J].

Feld, Ron ;

Sridhar, Srikala S. ;

Shepherd, Frances A. ;

Mackay, Jean A. ;

Evans, William K. .

JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (04) :367-376

[6] Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy [J].

Gonzalez, G ;

Crombet, T ;

Torres, F ;

Catala, M ;

Alfonso, L ;

Osorio, M ;

Neninger, E ;

Garcia, B ;

Mulet, A ;

Perez, R ;

Lage, R .

ANNALS OF ONCOLOGY, 2003, 14 (03) :461-466

[7] The polymorphic epithelial mucin: Potential as an immunogen for a cancer vaccine [J].

Graham, RA ;

Burchell, JM ;

TaylorPapadimitriou, J .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (02) :71-80

[8] Autologous dendritic cell vaccines for non-small-cell lung cancer [J].

Hirschowitz, EA ;

Foody, T ;

Kryscio, R ;

Dickson, L ;

Sturgill, J ;

Yannelli, J .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2808-2815

[9] Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells [J].

Hirschowitz, Edward A. ;

Foody, Terry ;

Hidalgo, Giovanna E. ;

Yannelli, John R. .

LUNG CANCER, 2007, 57 (03) :365-372

[10]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

← 1 2 3 →